Peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP12)–Calcineurin complex (FKBP12–CaN)

The Peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP12)–Calcineurin complex is a pivotal molecular assembly in the regulation of the adaptive immune response and the primary target for the immunosuppressant drug tacrolimus (FK506) [StatPearls, 2023]. This complex is formed when tacrolimus binds to the immunophilin FKBP12, creating a gain-of-function complex that specifically targets and inhibits calcineurin, a calcium/calmodulin-dependent serine/threonine protein phosphatase [UniProt P62942; UniProt P16298]. Calcineurin's essential biological role involves the dephosphorylation of the Nuclear Factor of Activated T-cells (NFAT), a transcription factor that, once dephosphorylated, translocates to the nucleus to drive the expression of interleukin-2 (IL-2) and other cytokines necessary for T-cell activation [PubMed, 7566031; NIH, 2022]. By sterically hindering calcineurin's active site, the FKBP12–tacrolimus complex effectively shuts down this signaling pathway, making it a cornerstone therapy for preventing organ transplant rejection and treating autoimmune disorders [StatPearls, 2023]. However, the ubiquitous expression of calcineurin leads to significant therapeutic challenges, including dose-limiting nephrotoxicity and neurotoxicity, necessitating careful therapeutic drug monitoring [StatPearls, 2023].

Other names

FK506-binding protein 12–Calcineurin complexFKBP1A–PPP3C complexTacrolimus–FKBP12–Calcineurin complexFKBP12–PP2B complex

Inhibition of calcineurin phosphatase activity via ternary complex formation with FKBP12 and a macrolide drug, preventing NFAT nuclear translocation and cytokine production [StatPearls, 2023].